The application of in vivo bioluminescent imaging in
infectious disease research has significantly increased over the past years. The detection of transgenic parasites expressing wildtype
firefly luciferase is however hampered by a relatively low and heterogeneous tissue penetrating capacity of emitted light. Solutions are sought by using
codon-optimized red-shifted
luciferases that yield higher expression levels and produce relatively more red or near-infrared light, or by using modified bioluminescent substrates with enhanced cell permeability and improved luminogenic or pharmacokinetic properties. In this study, the in vitro and in vivo efficacy of two modified bioluminescent substrates, CycLuc1 and AkaLumine-HCl, were compared with that of
D-luciferin as a gold standard. Comparisons were made in experimental and insect-transmitted animal models of
leishmaniasis (caused by intracellular Leishmania species) and
African trypanosomiasis (caused by extracellular Trypanosoma species), using parasite strains expressing the red-shifted
firefly luciferase PpyRE9. Although the luminogenic properties of AkaLumine-HCl and
D-luciferin for in vitro parasite detection were comparable at equal substrate concentrations, AkaLumine-HCl proved to be unsuitable for in vivo
infection follow-up due to high background signals in the liver. CycLuc1 presented a higher in vitro luminescence compared to the other substrates and proved to be highly efficacious in vivo, even at a 20-fold lower dose than
D-luciferin. This efficacy was consistent across
infections with the herein included intracellular and extracellular parasitic organisms. It can be concluded that CycLuc1 is an excellent and broadly applicable alternative for
D-luciferin, requiring significantly lower doses for in vivo bioluminescent imaging in rodent models of
leishmaniasis and
African trypanosomiasis.